Can Transforming Growth Factor Beta Affect Breast Cancer by Targeting MicroRNA 195?

Abstract

Background: Breast cancer is commonest non-skin cancer and is the second cause of cancer death in women. miRNA-195 is a tumor suppressor that is down-regulated in many cancers. TGF-β is an inflammatory cytokine that stimulates or inhibits miRNA maturation.

Aim: Detect level of miRNA-195 in metastatic & non-metastatic breast cancer patients and study its role in tumorigenesis of breast cancer via possible association with the inflammatory cytokine, TGF-β.

Methods: Expression of miRNA-195 and level of TGF-β were detected in 60 breast cancer female patients and 20 controls using quantitative real-time PCR and ELISA respectively.

Results: MiRNA-195 expression was significantly lower while TGF-β level was significantly higher in metastatic cancer patients compared to non-metastatic patients and healthy controls. Negative correlation was found between miRNA-195 expression and TGF-β in breast cancer patients.

Conclusion: MiRNA-195 may play role as tumor suppressor of breast cancer, particularly in metastatic group, may be through TGF-β signaling.

Keywords: Breast cancer; MiRNA-195; TGF-β

Introduction

Breast cancer (BC) is the leading cause of cancer death among females. Breast cancer is a heterogeneous tumor; it has a wide array malignant characteristics and clinical features. Not only the diversity in molecular abnormalities, but also the aberrant post-transcriptional modulation of gene expression by microRNAs (miRNAs) contributes to the imbalance between oncogenes and tumor suppressors in BC [1].

MicroRNAs are a novel class of small non-coding single-stranded RNA molecules involved in various biological processes; post-transcriptional gene regulation which affects mRNA stability and protein translation, apoptosis, development, proliferation and differentiation. So, miRNAs play fundamental role in tumorigenesis [2]. They included in the regulation of the inflammatory microenvironment in cancer [3].

Inflammatory mediators constitute a major part of the tumor microenvironment. They also have important roles in regulation of tumor initiation, proliferation and metastasis. Transforming growth factor-β (TGF-β) is an inflammatory cytokine that contributes to both tumor suppression and promotion; but, its underlying mechanism is still unclear. Recent evidence suggests an association between TGF-β signaling and miRNAs, which provides new insight into the interactions occurring in the inflammatory microenvironment of the tumors [4].

Previous studies suggest that TGF-β pathway can stimulate or inhibit miRNA maturation [4]. One unique feature of TGF-β is its paradoxical role; it acts as a tumor suppressor in the low-malignant
stages of tumorigenesis, whereas it promotes proliferation of the high-malignant cancer cells. The mechanisms by which TGF-β affects miRNA expression are either transcriptional or post-transcriptional [5]. The most prominent examples of miRNAs that are down-regulated by TGF-β signaling are miRNA-200, miRNA-584, miRNA-34a and miRNA-450b-5p. Whereas others up-regulated by TGF-β signaling are miRNA-21, miRNA-181, miRNA-494, and miRNA-10 [4]. MicroRNA-195 (miRNA-195) is a tumor suppressor as it is down-regulated in many cancers as hepatocellular, bladder, gastric, tongue, ovarian, peritoneal, adrenocortical, and colorectal. However, the results of the studies that examined the role of miRNA-195 in breast cancer progression and carcinogenesis is still inconsistent [3].

Materials and Methods

Study subjects

The study included 60 Egyptian women with breast cancer at different stages, their age ranged from (23-76 years). They were recruited from KasrAlainy hospital. Patients were diagnosed by clinical examination and confirmed by mammography and surgical biopsies.20 Healthy controls recruited during routine checkup, who were proven to be healthy with no family history of breast cancer.

Informed consent was obtained from the participants in this study after ethical committee approval from Medical Biochemistry Department, Faculty of Medicine Cairo University. All cases were subjected to estimation of expression level of miRNA 195 and TGF-β in serum.

The studied subjects were divided into two groups as follows

**Group I:** (n=20) healthy females as a control group with no family history of breast cancer, or any other diseases.

**Group II:** (n=34) non-metastatic breast cancer patients with or without nodal affection.

**Group III:** (n=26) metastatic breast cancer patients with nodal affection and distant metastasis (bone, liver and lung).

Blood sampling

Blood samples were collected from all subjects, 60 breast cancer patients and 20 healthy females as normal controls. Serum was separated from blood sample and stored at–80°C to be used for detecting level of miRNA-195 using qRT PCR and level of TGF-β by ELISA.

Detection of miRNA195 gene expression by quantitative real-time PCR: RNA extraction

Total RNA was extracted from 100μL of serum using (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. The concentration and purity of RNA were determined using NanoDrop® ND-1000.

RNA (5μg) was used per 20 μL reaction to generate cDNA using Gene-specific primers from the TaqMan microRNA Assays and reagents from the TaqMan microRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA), real-time PCR was carried out using an Invitrogen kit. Primers for miR-195 supplied from Applied Biosystems (TaqMan miRNA Assays ID 000452) in Step One Plus (Applied Biosystem, USA) device. MicroRNA expressions were normalized to small RNA U6, with the similar efficiency of microRNAs. Data of quantitative RT-PCR were demonstrated by nominal CT value (normalized to U6), and fold changes were calculated by ΔΔCt. The ΔΔCt (ΔΔCt=ΔC samples–ΔCtcontrol) to qualify the expression rate of miR-195.

Detection of TGF-β using ELISA

TGF-β was detected by Quantikine® ELISA kit supplied by (R&D systems, USA, Catalog Number DB100B) according to manufacturer instruction.

Statistical analysis

Data were coded and entered using the statistical package SPSS (Statistical Package for the Social Sciences) version 24. Data was summarized using mean, standard deviation, median deviation in quantitative data and using frequency (count) and relative frequency (percentage) for categorical data using the non-parametric Kruskal-Wallis and Mann-Whitney tests [5]. Correlations between quantitative variables were done using Spearman correlation coefficient [6]. P-values less than 0.05 were considered as statistically significant.

Results

Clinical characteristics of the patients

Clinical characteristics between metastatic and non-metastatic groups were compared showing no statistically significant difference about menopausal status (p=0.255) and family history (p=0.223), while staging was significantly different between both groups (p<0.001), as shown in Table 1.

### Table 1

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Metastasis</th>
<th>No metastasis</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Menopause</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>21</td>
<td>80.8%</td>
<td>23</td>
</tr>
<tr>
<td>Post</td>
<td>5</td>
<td>19.2%</td>
<td>11</td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>9</td>
<td>34.6%</td>
<td>7</td>
</tr>
<tr>
<td>No</td>
<td>17</td>
<td>65.4%</td>
<td>27</td>
</tr>
<tr>
<td><strong>Staging</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>0</td>
<td>0.0%</td>
<td>17</td>
</tr>
<tr>
<td>II then III</td>
<td>1</td>
<td>3.8%</td>
<td>0</td>
</tr>
<tr>
<td>III</td>
<td>0</td>
<td>0.0%</td>
<td>17</td>
</tr>
<tr>
<td>III then IV</td>
<td>9</td>
<td>34.6%</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>16</td>
<td>61.5%</td>
<td>0</td>
</tr>
</tbody>
</table>
Pathological characteristics of the patients

Comparing pathological data of metastatic and non-metastatic groups showed no statistically significant difference in ER (p=0.234), PR (p=0.956), site (p=0.155) and histological type (p=0.114). Whereas, HER-2 status (p=0.016) and molecular subtypes (p=0.001) were statistically significant, as shown in Table 2.

Serum level of MiRNA-195 among groups

The expression of miRNA-195 was significantly lower in metastatic group (0.23 ± 0.20) rather than in the non-metastatic one (0.61 ± 0.15). Both showed significant decrease compared to control group with p value (<0.001), as shown in Figure 1.

Serum level of TGF-β among different groups

The serum level of TGF-β was significantly higher in metastatic group (65.90 ± 17.93) rather than in the non-metastatic one (0.61 ± 0.15). Both showed significant increase compared to control group with p value (<0.001), as shown in Figure 2.

Comparison between miRNA and TGF-β regarding stage at diagnosis, single or multiple organs metastatic disease and Patients diagnosed as metastatic disease from the start & those developed metastasis after period of time

As shown in Table 3, For subgroup analysis among non-metastatic group according to stage at diagnosis: there was no statistically significant difference (p=0.849) in miRNA-195 expression between stage II group patients (0.61±0.16) and stage III group (0.60±0.15). Also, there was no significant difference (p=0.184) between patients with Stage II (69.76 ± 17.99) and stage III (62.03 ± 17.53) regarding TGF-β.

As well as in metastatic group, there was no significant difference (p=0.391) in serum miRNA-195 expression between patients with single organ of metastasis (0.27 ± 0.24) and patients with multiple organs of metastasis (0.17 ± 0.07). As well as serum TGF-β level, there was no significant difference (p=0.586) between patients with single organ of metastasis (146.40 ± 31.96) and in patients with multiple organ of metastasis (140.70 ± 53.35).

Also, no significant difference (p=0.452) in miRNA-195 expression between patients who were diagnosed as non-metastatic & developed metastasis after period of time (0.21±0.11) and those diagnosed as metastatic from the start (0.25±0.24). Serum TGF-β showed significantly lower (p=0.004) in patients who were diagnosed as non-metastatic & developed metastasis after period of time (122.65 ± 17.50) rather than those diagnosed as metastatic from the start (157.60 ± 30.67).

Association between miRNA-195, TGF-β and hormonal status (ER & PR)

There was no significant difference between serum miRNA-195 level and hormonal status for both ER and PR as well as the relation between serum TGF-β level & hormonal status for both ER & PR as shown in Table 4.
### Table 3 Comparison between miRNA and TGF-β regarding stage at diagnosis, single or multiple organs metastatic disease, and Patients diagnosed as metastatic disease from the start and those developed metastasis after period of time.

<table>
<thead>
<tr>
<th>P value</th>
<th>TGF-β (pg/ml) Mean ± Standard deviation</th>
<th>P value</th>
<th>miRNA 195 Mean ± Standard deviation</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.184</td>
<td>69.76 ± 17.99</td>
<td>0.849</td>
<td>0.61 ± 0.16</td>
<td>Stage in non-metastatic group II</td>
</tr>
<tr>
<td>0.586</td>
<td>62.03 ± 17.53</td>
<td>0.391</td>
<td>0.27 ± 0.24</td>
<td>Single organs metastatic disease</td>
</tr>
<tr>
<td>0.004</td>
<td>146.40 ± 31.96</td>
<td>0.452</td>
<td>0.25 ± 0.24</td>
<td>Developed metastasis after period of time</td>
</tr>
<tr>
<td></td>
<td>140.57 ± 31.35</td>
<td></td>
<td>0.21 ± 0.11</td>
<td>Developed metastasis after period of time</td>
</tr>
<tr>
<td></td>
<td>57.60 ± 30.67</td>
<td></td>
<td>0.21 ± 0.11</td>
<td>Developed metastasis after period of time</td>
</tr>
</tbody>
</table>

### Table 4 Association between miRNA-195 and TGF-β regarding (ER&PR) status.

<table>
<thead>
<tr>
<th>Association</th>
<th>miRNA 195 Mean ± Standard Deviation</th>
<th>P value</th>
<th>TGF-β (pg/ml) Mean ± Standard Deviation</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER positive</td>
<td>0.45 ± 0.23</td>
<td>0.570</td>
<td>94.33 ± 40.84</td>
<td>0.202</td>
</tr>
<tr>
<td>ER negative</td>
<td>0.43 ± 0.34</td>
<td></td>
<td>117.81 ± 58.33</td>
<td></td>
</tr>
<tr>
<td>PR positive</td>
<td>0.44 ± 0.24</td>
<td>0.969</td>
<td>92.88 ± 41.71</td>
<td>0.156</td>
</tr>
<tr>
<td>PR positive</td>
<td>0.46 ± 0.29</td>
<td></td>
<td>112.68 ± 51.84</td>
<td></td>
</tr>
</tbody>
</table>

**Association between miRNA-195, TGF-β & molecular subtypes**

The level of miRNA-195 was higher for luminal A patients (0.60 ± 0.29), followed by TNBC subtype then luminal B then HER-2 enriched subtype with no significant difference as shown in Figure 3.

There was higher level of TGF-β for HER-2 enriched patients (124.45 ± 51.99), followed by TNBC then luminal B then luminal A no significant difference (Figure 4).

**Discussion and conclusion**

Breast cancer is the commonest non-skin cancer and it is the second cause of cancer death in women worldwide [7]. Early detection of breast cancer is the key to successful treatment and patient survival [8]. Screening techniques are of limited use in screening due to their reduced sensitivity and specificity [8]. So, searching for effective non-invasive biomarkers is vital for the screening of breast cancer.

MicroRNA (miRNA) is a non-coding short RNA; about 22 nucleotides. miRNAs are estimated to regulate at least the third of human genes. They contribute by either negative or positive regulation [9]. Previous studies reported that the aberrant miRNAs expression had been implicated in the development and progression of breast cancer in addition to their involvement in the tumor-associated signal transduction pathways [8]. Transforming growth factor-β (TGF-β) is an inflammatory cytokine that contributes to both tumor suppression and promotion; but, its underlying mechanisms still unclear. Recent evidence suggests an association between TGF-β signaling and miRNAs, which provides new insight into the interactions occurring in the inflammatory microenvironment of the tumors [2].

MicroRNA-195 (miR-195) is a tumor suppressor as it is down-regulated in many cancers as hepatocellular, bladder, gastric, tongue, ovarian, peritoneal, adrenocortical, and colorectal. However, the results of the studies that examined the role of miR-195 in breast cancer progression and carcinogenesis is still inconsistent [10].

The aim of this work was to detect the level of microRNA-195 in metastatic and non-metastatic breast cancer patients and to study its role in tumorigenesis of breast cancer through its possible association with the inflammatory cytokine, TGF-β.

As regards clinicopathological data, [11] determined that worse prognosis of breast cancer was associated with overexpression of HER-2; as it was associated with premenopausal status, invasive ductal carcinoma and estrogen receptor positive tumors.

Regarding miRNA-195 level among metastatic group, [12] who reported that miRNA-195 expression was significantly decreased in 40 breast cancer specimens when compared with that in the adjacent normal breast tissues using quantitative polymerase chain reaction (qPCR), they also induced exogenous over-expression of miRNA-195 that leads to reduced cell colony formation, suppressed cell migration and caused an accumulation of cells in the G1 phase of the cell cycle. All of their data suggest that miRNA-195 is a tumor suppressor that may inhibit carcinogenesis in human breast cancer.

Also, these results were in accordance to [10] who compared miRNA-195 in 210 primary breast cancer and 102 age-matched normal serum samples obtained from healthy females using real-time RT-PCR. miRNA-195 was down-regulated in breast cancer compared with control samples [13], who reported that miRNA-195 was found to be significantly downregulated in breast cancer tissues and cell lines.

For subgroup analysis among non-metastatic group according to stage at diagnosis; [13] reported no significant differences of miRNA-195 expression among different breast cancer stages. Regarding the serum level of TGF-β among metastatic group, [14] who used the immunohistochemistry to examine TGF-β protein expression in 497 breast cancer tissues and 40 benign breast tumor tissues as controls, and reported that the positive staining of TGF-β was mainly observed on the cytoplasm of cells in the breast cancer tissues but rarely detected in the benign breast tissues. In addition, [14] compared the TGF-β positive group with those with TGF-β negative staining, finding that the TGF-β positive group had poor differentiation in histology.

The result of [15] also supported this current study; as they treated MCF-7 and MDA-MB-231 breast cancer cells with TGF-β1; showing that TGF-β1 significantly induced the occurrence of epithelial mesenchymal transition, migration, invasion and metastasis in both cell lines.

The results of the present study was also in accordance to [16] who used ELISA to detect the level of TGF-β in the 24-hours drained fluid from the wound of breast-conserving surgery in 23 patients with breast cancer patients; finding that its level was increased.

Also the association between miRNA-195 expression and hormonal status was studied for both Estrogen receptors (ER) and Progesterone receptors (PR) [13], showed no significant difference of miRNA-195 expression neither between ER positive versus ER negative tumors, nor between PR positive and PR negative tumors. In addition, results of [10], reported no significant relationships between miRNA-195 expression and other clinic pathological parameters as ER or PR status of breast cancer. [17] who analyzed the expression status of miRNA-195 in different breast cancer subtypes. Their data obtained that the expression of miRNA-195 was significantly down-regulated in HER2-positive breast epithelial cells compared to normal cells. Also, it was significantly downregulated in the HER2-positive subtype compared to luminal subtypes (luminal A & luminal B) of breast cancers. Hence, miRNA-195 expression was significantly down-regulated in aggressive subtypes of breast cancers. Also, [18] who reported that the expression of miRNA-195 was found to be significantly downregulated in samples of TNBC patients when compared to their age matched healthy samples, measured using quantitative real-time PCR.

As regards the association between serum TGF-β level and molecular subtypes, [19] who measured mRNA expression and protein levels of TGF-β1 and β2 in human breast cancer cells lines (TNBC cells and non-TNBC cells) using real-time polymerase chain reaction (RT-PCR) and ELISA respectively, and reported that both TGF-β1 and TGF-β2 protein expression was significantly increased.

**Conflicts of Interest**

Author does not have any conflict of interest to declare.

**References**


